Aflibercept Injection for Proliferative Diabetic Retinopathy
Part of paid clinical trials in Oklahoma City, Oklahoma.
- Sponsor
- University of Oklahoma
- Study ID
- NCT01805297
- Phase
- PHASE2
- Status
- Completed
Conditions
- Vitreous Hemorrhage
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Intravitreal Aflibercept Injection — DRUGOne time 2.0mg aflibercept injection, following pars plana vitrectomy.
- Standard Vitrectomy — OTHERSurgical intervention
Study Details
To evaluate the ocular and systemic safety of intravitreal aflibercept injection in patients undergoing Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy.
Key Dates
- Start date
- Mar 31, 2013
- Status verified
- Dec 2023
- Primary completion
- Feb 28, 2014
- Completion
- Nov 30, 2015
Study Design
- Enrollment
- 12 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: Vitrectomy with Aflibercept InjectionPreoperative 2.0mg intravitreal aflibercept and vitrectomy with intraoperative 2.0mg intravitreal aflibercept injection.
- Active Comparator: Standard VitrectomyPreoperative 2.0mg intravitreal aflibercept and standard of care vitrectomy.
Primary Outcome Measure
Rate of Resolved Post-operative Vitreous Hemorrhage. [ Time Frame: 24 weeks ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Dean McGee Eye Institute | Oklahoma City | Oklahoma | 73104 | - |
Find similar trials in Oklahoma City, OK
By research site